Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis

Inclusion Criteria: * Diagnosis of idiopathic pulmonary fibrosis * Disease progression despite six months of treatment (steroids with/without azathioprine or cyclophosphamide) defined by at least one of the following: * Increased symptoms * Decline in forced vital capacity of at least 10% * Decline in diffusion capacity for carbon monoxide of at least 20% * Increased infiltrate on CXR or high resolution CT scan * Taking \< 15 mg prednisone for at least 30 days prior to screening * Age 35-80, inclusive * Able to understand a written informed consent and comply with the study protocol Exclusion Criteria: * Significant environmental exposure * Diagnosis of collagen vascular disease * Evidence of active infection * Clinically significant cardiac disease: * Myocardial infarction, coronary artery bypass or angioplasty within 6mo * Unstable angina pectoris * Congestive heart failure requiring hospitalization within 6 months * Uncontrolled arrhythmia * Poorly controlled or severe diabetes mellitus * Pregnancy or lactation * Women of childbearing potential not using a medically approved means of contraception (i.e. oral contraceptives, intrauterine devices, diaphragm, Norplant) * Current enrollment in another experimental protocol Physiologic Criteria: * FEV1/FVC \< 0.60 Laboratory Criteria: * Total bilirubin \> 1.5 X upper limit normal * AST or ALT \> 3X upper limit normal * Alkaline phosphatase \> 3X upper limit normal * White blood cell count \< 2,500/mm3 * Hematocrit \< 30% * Platelets \< 100,000/mm3 * Prothrombin time INR \> 1.5